ArticleJournal of cellular and molecular medicine2025
Niosomal Hydrogel Loaded With Bromelain: A Promising Solution for Reducing Skin Collagen in Scleroderma Patients.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Niosomal Hydrogel Loaded With Bromelain: A Promising Solution for Reducing Skin Collagen in Scleroderma Patients.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin fibrosis in scleroderma is a chronic and debilitating condition that affects the quality of life of patients. In this study, we fabricated a niosomal hydrogel containing bromelain to reduce skin collagen and improve skin softness in scleroderma patients. The niosomes were prepared using the thin film hydration method and exhibited a drug loading efficiency of 52.2%. They demonstrated high monodispersity, with mean sizes lower than 200 nm. The results showed a significant reduction in mean dermal thickness from 1195 μm before treatment to 750 μm after the 2-month treatment period. This reduction in dermal thickness and improved skin softness can be attributed to the decomposition of accumulated skin collagen in individuals with scleroderma. Additionally, the treatment was found to be effective in reducing skin collagen levels compared to conventional treatment options that merely impede collagen synthesis. The current study underscores the potential of bromelain niosomal hydrogel as a promising strategy for managing skin fibrosis in scleroderma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.